Stockscreener 앱 받기
1.31%
시간 외 거래:
전일 마감가:
$26.81
열려 있는:
$26.82
하루 거래량:
42.76M
Relative Volume:
0.91
시가총액:
$154.44B
수익:
$62.58B
순이익/손실:
$7.79B
주가수익비율:
20.04
EPS:
1.3551
순현금흐름:
$9.08B
1주 성능:
+2.18%
1개월 성능:
-1.63%
6개월 성능:
+10.54%
1년 성능:
+1.95%
1일 변동 폭
$26.52
$27.29
1주일 범위
$26.20
$27.29
52주 변동 폭
$20.91
$27.94
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, NVS, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.16 | 152.45B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,001.35 | 900.48B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.71 | 584.62B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.01 | 402.17B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
161.59 | 310.63B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.99 | 302.33B | 58.80B | 10.24B | 8.98B | 3.2788 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer, ASKA Pharma to co-promote RSV vaccine Abrysvo in Japan - BioSpectrum Asia
BMO Maintains Outperform on Pfizer (PFE) March 2026 - Meyka
Pfizer's payout ratio is still over 100%. Is a dividend cut inevitable? - MSN
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent - TechStock²
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance
BMO reiterates Pfizer stock Outperform rating on antibody data - Investing.com
Pfizer (PFE) Advances Tilrekimig for Atopic Dermatitis with Posi - GuruFocus
Pfizer reports positive data from Phase 2 study for atopic dermatitis antibody (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Reports Promising Results from Phase 2 Atopic Derma - GuruFocus
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study - Yahoo Finance
Pfizer shares dip despite positive trial results for skin condition drug - Investing.com Nigeria
Pfizer’s tilrekimig meets Phase 2 trial endpoint for dermatitis - Investing.com India
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis - Business Wire
Streptococcus Market Is Going to Boom | AbbVie • Pfizer • Merck & Co. • GlaxoSmithKline - openPR.com
Anti Infective Vaccines Market Witnessing Massive Growth - openPR.com
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Where Will Eli Lilly Stock Be in 10 Years? - The Motley Fool
Is Pfizer Inc. stock gaining market share2025 Bull vs Bear & Community Consensus Trade Signals - Naître et grandir
American Century Companies Inc. Sells 546,598 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - BioPharma Dive
Pfizer Obesity Nod In China And Cancer Wins Reframe Long Term Growth - Yahoo Finance
Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline - TipRanks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside - Traders Union
Pfizer (PFE) Gains Approval for Obesity Drug in China - GuruFocus
Pfizer's (PFE) GLP-1 Treatment Gains Approval in China - GuruFocus
Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Edgar Lomax Co. VA Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Beddow Capital Management Inc. Sells 62,275 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer's Weight Loss Injection GLP-1 Ecnoglutide Injection Approved in CN - AASTOCKS.com
China Greenlights Pfizer’s Obesity Injection as Generic Rivals Approach - FXLeaders
Pfizer Secures China Nod for Obesity Drug as Generics Loom - Bloomberg
China approves Pfizer GLP-1 drug for weight management - Yahoo Finance
China approves Pfizer GLP-1 drug for weight loss - Reuters
Pfizer Gets OK For $29M SEC Payout From Insider Case - Law360
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund - Reuters
Pfizer’s Comirnaty Update: What U.S. Patients Need To Know Now - AD HOC NEWS
Pfizer Arbitration Confidentiality Rule Is Lawful, NLRB Says - Law360
Smart Money Is Betting Big In PFE Options - Benzinga
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate - Yahoo Finance
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com
Retinal Vein Occlusion Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer - Barchart.com
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? - TradingView
Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC - MarketBeat
Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE - MarketBeat
Pfizer: Obesity Hype And Vaccine Policy Shocks (NYSE:PFE) - Seeking Alpha
Skeletal Dysplasia Market - GlobeNewswire Inc.
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Finviz
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.66%
1.32%
자본화:
|
볼륨(24시간):